Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches. Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care. Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections: Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed resultsArticle Highlights – an executive summary of the author’s most critical points.
《抗癌治疗专家评论》（ISSN 1473-7140）提供了专家对癌症治疗主要趋势的评估和评论，并强调了新的治疗和诊断方法的性能。覆盖范围包括肿瘤管理、新药、抗癌药物和化疗、生物治疗、癌症疫苗、治疗适应症、生物标志物和诊断以及治疗指南。所有文章都经过严格的同行评审，该杂志对癌症护理决策做出了重要贡献。每项审查的全面覆盖范围由独特的专家审查格式补充，包括以下部分：专家意见-对文章中数据的个人观点，对未来可能重要的发展的讨论，以及随着进一步研究产生更详细的结果而可能变得令人兴奋的研究途径文章要点-作者最关键观点的执行摘要。
Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies
来源期刊：Expert Review of Anticancer TherapyDOI：10.1080/14737140.2019.1693893
Capmatinib for the treatment of non-small cell lung cancer
来源期刊：Expert Review of Anticancer TherapyDOI：10.1080/14737140.2019.1643239
The landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanib
来源期刊：Expert Review of Anticancer TherapyDOI：10.1080/14737140.2019.1686979
Personalizing surgical margins in retroperitoneal sarcomas: an update
来源期刊：Expert Review of Anticancer TherapyDOI：10.1080/14737140.2019.1625774
Cabozantinib for the treatment of hepatocellular carcinoma
来源期刊：Expert Review of Anticancer TherapyDOI：10.1080/14737140.2019.1674141
The role of circulating free DNA in the management of NSCLC
来源期刊：Expert Review of Anticancer TherapyDOI：10.1080/14737140.2019.1548938
The role of combination chemo-immunotherapy in advanced non-small cell lung cancer
来源期刊：Expert Review of Anticancer TherapyDOI：10.1080/14737140.2019.1631800
Remodeling the cancer epigenome: mutations in the SWI/SNF complex offer new therapeutic opportunities
来源期刊：Expert Review of Anticancer TherapyDOI：10.1080/14737140.2019.1605905
Emotions in the room: common emotional reactions to discussions of poor prognosis and tools to address them
来源期刊：Expert Review of Anticancer TherapyDOI：10.1080/14737140.2019.1651648
Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer
来源期刊：Expert Review of Anticancer TherapyDOI：10.1080/14737140.2019.1596030
Management of immune-related adverse events resulting from immune checkpoint blockade
来源期刊：Expert Review of Anticancer TherapyDOI：10.1080/14737140.2019.1562342
The role of metastasectomy in advanced renal cell carcinoma
来源期刊：Expert Review of Anticancer TherapyDOI：10.1080/14737140.2019.1625772
The prognostic role of circulating tumor cells in colorectal cancer
来源期刊：Expert Review of Anticancer TherapyDOI：10.1080/14737140.2019.1699065
Oral and Oropharyngeal squamous cell carcinoma: prognostic and predictive parameters in the etiopathogenetic route
来源期刊：Expert Review of Anticancer TherapyDOI：10.1080/14737140.2019.1561288
An update on current and future treatment options for chondrosarcoma
来源期刊：Expert Review of Anticancer TherapyDOI：10.1080/14737140.2019.1659731
Quality measures improving endoscopic screening of colorectal cancer: a review of the literature
来源期刊：Expert Review of Anticancer TherapyDOI：10.1080/14737140.2019.1565999
Systemic treatment of advanced hepatocellular cancer: new hope on the horizon
来源期刊：Expert Review of Anticancer TherapyDOI：10.1080/14737140.2019.1585245
An update on genetic risk assessment and prevention: the role of genetic testing panels in breast cancer
来源期刊：Expert Review of Anticancer TherapyDOI：10.1080/14737140.2019.1659730
ALK testing methods: is there a winner or loser?
来源期刊：Expert Review of Anticancer TherapyDOI：10.1080/14737140.2019.1562343
Have treatment protocols for primary CNS lymphoma advanced in the past 10 years
来源期刊：Expert Review of Anticancer TherapyDOI：10.1080/14737140.2019.1677157
Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer
来源期刊：Expert Review of Anticancer TherapyDOI：10.1080/14737140.2019.1654378
Recent advances with cyclin-dependent kinase inhibitors: therapeutic agents for breast cancer and their role in immuno-oncology
来源期刊：Expert review of anticancer therapyDOI：10.1080/14737140.2019.1615889
Can CDK4/6 inhibitors cause fatal lung injury?
来源期刊：Expert Review of Anticancer TherapyDOI：10.1080/14737140.2019.1674651
Prodrugs for targeted cancer therapy
来源期刊：Expert Review of Anticancer TherapyDOI：10.1080/14737140.2019.1615890
Desmoplastic melanoma: a brief review and the efficacy of immunotherapy
来源期刊：Expert Review of Anticancer TherapyDOI：10.1080/14737140.2019.1574573
The overall potential of CD47 in cancer immunotherapy: with a focus on gastrointestinal tumors
来源期刊：Expert Review of Anticancer TherapyDOI：10.1080/14737140.2019.1689820
Management of residual masses in testicular germ cell tumors
来源期刊：Expert Review of Anticancer TherapyDOI：10.1080/14737140.2019.1580146
Cadmium: a new risk factor for endometrial cancer?
来源期刊：Expert Review of Anticancer TherapyDOI：10.1080/14737140.2019.1596029
Incorporating molecular biomarkers into clinical practice for gastric cancer
来源期刊：Expert Review of Anticancer TherapyDOI：10.1080/14737140.2019.1659136
Beyond immunohistochemistry and immunocytochemistry: a current perspective on galectin-3 and thyroid cancer
来源期刊：Expert Review of Anticancer TherapyDOI：10.1080/14737140.2019.1693270
An update on advanced dual-energy CT for head and neck cancer imaging
来源期刊：Expert Review of Anticancer TherapyDOI：10.1080/14737140.2019.1626234
Interpretation of ceritinib clinical trial results and future combination therapy strategies for ALK-rearranged NSCLC
来源期刊：Expert Review of Anticancer TherapyDOI：10.1080/14737140.2019.1699792
Elotuzumab in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma
来源期刊：Expert Review of Anticancer TherapyDOI：10.1080/14737140.2019.1685879
Targeting angiogenesis in metastatic renal cell carcinoma
来源期刊：Expert Review of Anticancer TherapyDOI：10.1080/14737140.2019.1574574
Oncologic therapies associated with cardiac toxicities: how to minimize the risks
来源期刊：Expert Review of Anticancer TherapyDOI：10.1080/14737140.2019.1596804
Value of quantitative and qualitative analyses of serum and urine cell-free DNA as diagnostic tools for bladder cancer: a meta-analysis
来源期刊：Expert Review of Anticancer TherapyDOI：10.1080/14737140.2019.1626723
Adjuvant therapeutic approaches of HER2-positive breast cancer with a focus on neratinib maleate
来源期刊：Expert Review of Anticancer TherapyDOI：10.1080/14737140.2019.1613892
Limited treatment options in refractory multiple myeloma: promising therapeutic developments
来源期刊：Expert Review of Anticancer TherapyDOI：10.1080/14737140.2020.1708721
An aspirin a day keeps ovarian cancer at bay?
来源期刊：Expert Review of Anticancer TherapyDOI：10.1080/14737140.2019.1626722
Third generation EGFR TKI landscape for metastatic EGFR mutant non-small cell lung cancer (NSCLC)
来源期刊：Expert Review of Anticancer TherapyDOI：10.1080/14737140.2019.1604228
Should chemotherapy still be used to treat all muscle invasive bladder cancer in the “era of immunotherapy”?
来源期刊：Expert Review of Anticancer TherapyDOI：10.1080/14737140.2019.1625773
The use of in vivo reflectance confocal microscopy for the diagnosis of melanoma
来源期刊：Expert Review of Anticancer TherapyDOI：10.1080/14737140.2019.1593829
Advancements in the clinical management of upper tract urothelial carcinoma
来源期刊：Expert Review of Anticancer TherapyDOI：10.1080/14737140.2019.1698295
Advances in the therapy of BRAFV600E metastatic colorectal cancer
来源期刊：Expert Review of Anticancer TherapyDOI：10.1080/14737140.2019.1661778
Stereotactic body radiotherapy in patients with multiple lung tumors: a focus on lung dosimetric constraints
来源期刊：Expert Review of Anticancer TherapyDOI：10.1080/14737140.2019.1686980
Optimizing adjuvant therapies for the treatment of gastric cancer: with a special focus on Asia
来源期刊：Expert Review of Anticancer TherapyDOI：10.1080/14737140.2019.1685877
Pertuzumab for the treatment of breast cancer
来源期刊：Expert Review of Anticancer TherapyDOI：10.1080/14737140.2019.1596805
What can we learn from the association between adolescent alcohol consumption and breast cancer risk?
来源期刊：Expert Review of Anticancer TherapyDOI：10.1080/14737140.2019.1586538
Chronic tyrosine kinase inhibitor (TKI) use in metastatic renal cell carcinoma (mRCC): can this lead to the adverse effect of hypogonadism?
来源期刊：Expert Review of Anticancer TherapyDOI：10.1080/14737140.2019.1609355
The impact of epidermal growth factor receptor mutations on the efficacy of definitive chemoradiotherapy in patients with locally advanced unresectable stage III non-small cell lung cancer: a systematic review and meta-analysis
来源期刊：Expert Review of Anticancer TherapyDOI：10.1080/14737140.2019.1621754
